TX-EMIST
2.11.2020 14:02:05 CET | Business Wire | Press release
EMist® Disinfection Solutions today announced the launch of the EX-7000 Tru Electrostatic™ Disinfectant Sprayer.
The EX-7000 is lightweight and ergonomic weighing in at just 14.9 pounds making it one-half lighter than other sprayers. Equipped with intelligent Charge Detect™ Technology, the EX-7000 electrostatic sprayer continuously detects the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue, ensuring the most comprehensive disinfectant coating in the industry, and reducing labor and chemical costs by 50 percent.
Disinfectant is first atomized, passes through an electrostatic-induction nozzle, charged using a bipolar power supply, and then discharged toward the target area. The bipolar supply causes the electrical charges to be alternatively redistributed, resulting in droplets having an excess of either positive or negative charges. These charged droplets are so attracted to the targeted area that they coat the sides, edges, and backside of surfaces.
EMist’s TruElectrostatic Disinfectant Sprayers are built on six core platforms, resulting in an electrostatic sprayer that provides 100 percent continuous electrostatic charge output, eliminates grounding, yielding superior, comprehensive coverage.
TruTechnology: EPIX Charge Detect Technology
Using EPIX Charge Detect Technology, the electrostatic sprayers continuously detect the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue. The discharged droplets wrap around surfaces. This wraparound effect creates an even, consistent and comprehensive coverage of chemical, reducing chemical and labor costs.
TruConfidence: Patented. Proven. Trusted.
Since the emergence of COVID-19, many companies have appeared overnight claiming they have electrostatic sprayers. When dealing with life-threatening pathogens, it’s critically important to know that the company you’re buying from is experienced, respected, and proven. EMist electrostatic sprayers are patented, backed by independent lab studies, used during the 2014 Ebola crisis, and developed by electrostatic industry veteran Mike Sides, who frequently works with the Department of Defense, Naval Entomology Center of Excellence, USDA, and the World Health Organization.
TruCharge: Best Performance
Electrostatic sprayer polarity matters. Most surfaces have a negative or neutral charge (the earth itself is negative). Per the EPA, electrostatic sprayers should impart a positive charge so that the positively charged disinfectant droplets are attracted to targeted negative or neutral surfaces. Positively charged droplets increase droplet adhesion and wrap.
TruDesign: Safer Operation
When spraying big areas, big buildings, or tight spaces, a cordless sprayer allows you to maneuver and move about freely. EMist sprayers are ergonomic, lightweight, and cordless. That means operators can take the sprayer to where the work needs to be done rather than relying on wall outlets at the work site. Portability is a clear advantage for any user who needs to go where the work is to get the job done right.
TruAssurance: User Safety
Per the EPA, electrostatic disinfectant sprayers should have a median droplet size greater than 40 microns. Droplets must be large enough to resist evaporation and drift but small enough that the droplets can change their trajectory when it comes close to a target. Most competitor sprayers produce droplets of less than 40 microns making them highly drift-prone and increasing user inhalation concerns. EMist sprayers maintain a median droplet size of 75 microns.
TruCost: Lower Total Cost of Ownership
Based on the need to disinfect large areas, manual application of disinfectants is a thing of the past. Electrostatic application is the new normal. Customers using EMist systems typically see up to 50 percent reduction in labor and chemical costs. Competitively priced, advanced and patented electrostatic technology, and proven performance provide an overall lower total cost of ownership.
EMist has announced a reservation program for purchasers who want to secure their units in December. The company will begin taking refundable $50 reservations on its official website starting on November 2 at 8 a.m. Central Time. The EX-7000 is available through EMist distributors at a list price of $3,995 USD.
About EMist
Headquartered in Fort Worth, Texas, EMist develops intelligent electrostatic disinfectant sprayers that make spaces healthier. For more information, visit EMist.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005026/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release
Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
